Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2015 (2015), Article ID 854015, 15 pages
http://dx.doi.org/10.1155/2015/854015
Review Article

Interactions between CYP3A4 and Dietary Polyphenols

Institute of Biochemistry, Food Science and Nutrition, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, P.O. Box 12, 76100 Rehovot, Israel

Received 14 October 2014; Revised 15 December 2014; Accepted 19 December 2014

Academic Editor: Cristina Angeloni

Copyright © 2015 Loai Basheer and Zohar Kerem. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. G. Denisov, T. M. Makris, S. G. Sligar, and I. Schlichting, “Structure and chemistry of cytochrome P450,” Chemical Reviews, vol. 105, no. 6, pp. 2253–2277, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. T. L. Domanski, Y. A. He, K. K. Khan, F. Roussel, Q. Wang, and J. R. Halpert, “Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity,” Biochemistry, vol. 40, no. 34, pp. 10150–10160, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. D. W. Nebert and D. W. Russell, “Clinical importance of the cytochromes P450,” The Lancet, vol. 360, no. 9340, pp. 1155–1162, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. P. R. O. de Montellano, Cytochrome P450: Structure, Mechanism, and Biochemistry, Springer, 3rd edition, 2005.
  5. D. R. Nelson, “The cytochrome P450 homepage,” Human Genomics, vol. 4, no. 1, pp. 59–65, 2009. View at Google Scholar · View at Scopus
  6. D. R. Nelson, “A world of cytochrome P450s,” Philosophical transactions of the Royal Society of London, Series B: Biological Sciences, vol. 368, no. 1612, Article ID 20120430, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. D. W. Nebert, K. Wikvall, and W. L. Miller, “Human cytochromes P450 in health and disease,” Philosophical transactions of the Royal Society of London. Series B, Biological sciences, vol. 368, no. 1612, Article ID 20120431, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. D. W. Nebert, D. R. Nelson, M. J. Coon et al., “The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature,” DNA and Cell Biology, vol. 10, no. 1, pp. 1–14, 1991. View at Publisher · View at Google Scholar · View at Scopus
  9. U. M. Zanger and M. Schwab, “Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation,” Pharmacology & Therapeutics, vol. 138, no. 1, pp. 103–141, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. F. P. Guengerich, “Cytochrome P450 and chemical toxicology,” Chemical Research in Toxicology, vol. 21, no. 1, pp. 70–83, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Ekins, D. M. Stresser, and J. A. Williams, “In vitro and pharmacophore insights into CYP3A enzymes,” Trends in Pharmacological Sciences, vol. 24, no. 4, pp. 161–166, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. K. S. Lown, D. G. Bailey, R. J. Fontana et al., “Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression,” The Journal of Clinical Investigation, vol. 99, no. 10, pp. 2545–2553, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. J. C. Kolars, K. S. Lown, P. Schmiedlin-Ren et al., “CYP3A gene expression in human gut epithelium,” Pharmacogenetics and Genomics, vol. 4, no. 5, pp. 247–259, 1994. View at Publisher · View at Google Scholar · View at Scopus
  14. C. S. Ferguson and R. F. Tyndale, “Cytochrome P450 enzymes in the brain: emerging evidence of biological significance,” Trends in Pharmacological Sciences, vol. 32, no. 12, pp. 708–714, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Ghosh, N. Marchi, N. K. Desai et al., “Cellular localization and functional significance of CYP3A4 in the human epileptic brain,” Epilepsia, vol. 52, no. 3, pp. 562–571, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. F. P. Guengerich, “Cytochrome P-450 3A4: regulation and role in drug metabolism,” Annual Review of Pharmacology and Toxicology, vol. 39, pp. 1–17, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. Z. Huang, M. J. Fasco, H. L. Figge, K. Keyomarsi, and L. S. Kaminsky, “Expression of cytochromes P450 in human breast tissue and tumors,” Drug Metabolism and Disposition, vol. 24, no. 8, pp. 899–905, 1996. View at Google Scholar · View at Scopus
  18. J. H. Lin, M. Chiba, and T. A. Baillie, “Is the role of the small intestine in first-pass metabolism overemphasized?” Pharmacological Reviews, vol. 51, no. 2, pp. 135–158, 1999. View at Google Scholar · View at Scopus
  19. M. F. Paine, H. L. Hart, S. S. Ludington, R. L. Haining, A. E. Rettie, and D. C. Zeldin, “The human intestinal cytochrome P450 ‘pie’,” Drug Metabolism & Disposition, vol. 34, no. 5, pp. 880–886, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Galetin, M. Gertz, and J. B. Houston, “Contribution of intestinal cytochrome P450-mediated metabolism to drug-drug inhibition and induction interactions,” Drug Metabolism and Pharmacokinetics, vol. 25, no. 1, pp. 28–47, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Yang, G. T. Tucker, and A. Rostami-Hodjegan, “Cytochrome P450 3A expression and activity in the human small intestine,” Clinical Pharmacology and Therapeutics, vol. 76, no. 4, article 391, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. M. F. Paine, M. Khalighi, J. M. Fisher et al., “Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism,” Journal of Pharmacology and Experimental Therapeutics, vol. 283, no. 3, pp. 1552–1562, 1997. View at Google Scholar · View at Scopus
  23. F. H. Karlsson, S. Bouchene, C. Hilgendorf, H. Dolgos, and S. A. Peters, “Utility of in vitro systems and preclinical data for the prediction of human intestinal first-pass metabolism during drug discovery and preclinical development,” Drug Metabolism and Disposition, vol. 41, no. 12, pp. 2033–2046, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Siissalo and A. T. Heikkinen, “In vitro methods to study the interplay of drug metabolism and efflux in the intestine,” Current Drug Metabolism, vol. 14, no. 1, pp. 102–111, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Gertz, J. D. Davis, A. Harrison, J. B. Houston, and A. Galetin, “Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations,” Current Drug Metabolism, vol. 9, no. 8, pp. 785–795, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. S. D. Hall, K. E. Thummel, P. B. Watkins et al., “Molecular and physical mechanisms of first-pass extraction,” Drug Metabolism and Disposition, vol. 27, no. 2, pp. 161–166, 1999. View at Google Scholar · View at Scopus
  27. D. G. Bailey, G. Dresser, and J. M. O. Arnold, “Grapefruit-medication interactions: forbidden fruit or avoidable consequences?” Canadian Medical Association Journal, vol. 185, no. 4, pp. 309–316, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Gertz, A. Harrison, J. B. Houston, and A. Galetin, “Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data,” Drug Metabolism and Disposition, vol. 38, no. 7, pp. 1147–1158, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. J. van Duynhoven, E. E. Vaughan, D. M. Jacobs et al., “Metabolic fate of polyphenols in the human superorganism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 1, pp. 4531–4538, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Williamson and M. N. Clifford, “Colonic metabolites of berry polyphenols: the missing link to biological activity?” British Journal of Nutrition, vol. 104, supplement 3, pp. S48–S66, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. L. S. Kaminsky and Q.-Y. Zhang, “The small intestine as a xenobiotic-metabolizing organ,” Drug Metabolism and Disposition, vol. 31, no. 12, pp. 1520–1525, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Martignoni, G. Groothuis, and R. de Kanter, “Comparison of mouse and rat cytochrome P450-mediated metabolism in liver and intestine,” Drug Metabolism and Disposition, vol. 34, no. 6, pp. 1047–1054, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Lindell, M. Lang, and H. Lennernäs, “Expression of genes encoding for drug metabolising cytochrome P450 enzymes and P-glycoprotein in the rat small intestine; comparison to the liver,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 28, no. 1, pp. 41–48, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. X. Cao, S. T. Gibbs, L. Fang et al., “Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model,” Pharmaceutical Research, vol. 23, no. 8, pp. 1675–1686, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Awortwe, P. S. Fasinu, and B. Rosenkranz, “Application of Caco-2 cell line in herb-drug interaction studies: current approaches and challenges,” Journal of Pharmacy and Pharmaceutical Sciences, vol. 17, no. 1, pp. 1–19, 2014. View at Google Scholar · View at Scopus
  36. N. Holmstock, F. J. Gonzalez, M. Baes, P. Annaert, and P. Augustijns, “PXR/CYP3A4-humanized mice for studying drug-drug interactions involving intestinal P-glycoprotein,” Molecular Pharmaceutics, vol. 10, no. 3, pp. 1056–1062, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Schroer, M. Kittelmann, and S. Lütz, “Recombinant human cytochrome P450 monooxygenases for drug metabolite synthesis,” Biotechnology and Bioengineering, vol. 106, no. 5, pp. 699–706, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. G. Regev-Shoshani, O. Shoseyov, and Z. Kerem, “Influence of lipophilicity on the interactions of hydroxy stilbenes with cytochrome P450 3A4,” Biochemical and Biophysical Research Communications, vol. 323, no. 2, pp. 668–673, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. L. Tang, L. Ye, C. Lv, Z. Zheng, Y. Gong, and Z. Liu, “Involvement of CYP3A4/5 and CYP2D6 in the metabolism of aconitine using human liver microsomes and recombinant CYP450 enzymes,” Toxicology Letters, vol. 202, no. 1, pp. 47–54, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. V. Grinkova, I. G. Denisov, M. A. McLean, and S. G. Sligar, “Oxidase uncoupling in heme monooxygenases: human cytochrome P450 CYP3A4 in Nanodiscs,” Biochemical and Biophysical Research Communications, vol. 430, no. 4, pp. 1223–1227, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Hamdane, H. Zhang, and P. Hollenberg, “Oxygen activation by cytochrome P450 monooxygenase,” Photosynthesis Research, vol. 98, no. 1–3, pp. 657–666, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. B. Meunier, S. P. de Visser, and S. Shaik, “Mechanism of oxidation reactions catalyzed by cytochrome P450 enzymes,” Chemical Reviews, vol. 104, no. 9, pp. 3947–3980, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. P. R. O. de Montellano and J. J. de Voss, “Substrate oxidation by cytochrome P450 enzymes,” in Cytochrome P450, pp. 183–245, Springer, New York, NY, USA, 3rd edition, 2005. View at Publisher · View at Google Scholar
  44. S.-F. Zhou, J.-P. Liu, and B. Chowbay, “Polymorphism of human cytochrome P450 enzymes and its clinical impact,” Drug Metabolism Reviews, vol. 41, no. 2, pp. 89–295, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. M. H. Choi, P. L. Skipper, J. S. Wishnok, and S. R. Tannenbaum, “Characterization of testosterone 11β-hydroxylation catalyzed by human liver microsomal cytochromes P450,” Drug Metabolism and Disposition, vol. 33, no. 6, pp. 714–718, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. N. Yasui-Furukori, M. Hidestrand, E. Spina, G. Facciolá, M. G. Scordo, and G. Tybring, “Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes,” Drug Metabolism & Disposition, vol. 29, no. 10, pp. 1263–1268, 2001. View at Google Scholar · View at Scopus
  47. Z. Liu and M. Hu, “Natural polyphenol disposition via coupled metabolic pathways,” Expert Opinion on Drug Metabolism and Toxicology, vol. 3, no. 3, pp. 389–406, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Manach, J. Hubert, R. Llorach, and A. Scalbert, “The complex links between dietary phytochemicals and human health deciphered by metabolomics,” Molecular Nutrition and Food Research, vol. 53, no. 10, pp. 1303–1315, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. M. P. Corcoran, D. L. McKay, and J. B. Blumberg, “Flavonoid basics: chemistry, sources, mechanisms of action, and safety,” Journal of Nutrition in Gerontology and Geriatrics, vol. 31, no. 3, pp. 176–189, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. G. F. Ferrazzano, I. Amato, A. Ingenito, A. Zarrelli, G. Pinto, and A. Pollio, “Plant polyphenols and their anti-cariogenic properties: a review,” Molecules, vol. 16, no. 2, pp. 1486–1507, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Scalbert and G. Williamson, “Dietary intake and bioavailability of polyphenols,” Journal of Nutrition, vol. 130, no. 8, pp. 2073S–2085S, 2000. View at Google Scholar · View at Scopus
  52. J. D. Lambert, S. Sang, and C. S. Yang, “Biotransformation of green tea polyphenols and the biological activities of those metabolites,” Molecular Pharmaceutics, vol. 4, no. 6, pp. 819–825, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. J. D. Lambert, S. Sang, and C. S. Yang, “Possible controversy over dietary polyphenols: benefits vs risks,” Chemical Research in Toxicology, vol. 20, no. 4, pp. 583–585, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Wanwimolruk and V. Prachayasittikul, “Cytochrome P450 enzyme mediated herbal drug interactions (part 1),” EXCLI Journal, vol. 13, pp. 347–391, 2014. View at Google Scholar · View at Scopus
  55. K. E. Heim, A. R. Tagliaferro, and D. J. Bobilya, “Flavonoid antioxidants: chemistry, metabolism and structure-activity relationships,” Journal of Nutritional Biochemistry, vol. 13, no. 10, pp. 572–584, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. I. Rodeiro, M. T. Donato, A. Lahoz, G. Garrido, R. Delgado, and M. J. Gómez-Lechón, “Interactions of polyphenols with the P450 system: possible implications on human therapeutics,” Mini-Reviews in Medicinal Chemistry, vol. 8, no. 2, pp. 97–106, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. L. M. Blanco-Colio, M. Valderrama, L. A. Alvarez-Sala et al., “Red wine intake prevents nuclear factor-κB activation in peripheral blood mononuclear cells of healthy volunteers during postprandial lipemia,” Circulation, vol. 102, no. 9, pp. 1020–1026, 2000. View at Publisher · View at Google Scholar · View at Scopus
  58. L. Hooper, P. A. Kroon, E. B. Rimm et al., “Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials,” The American Journal of Clinical Nutrition, vol. 88, no. 1, pp. 38–50, 2008. View at Google Scholar · View at Scopus
  59. J. P. E. Spencer, “Flavonoids and brain health: multiple effects underpinned by common mechanisms,” Genes and Nutrition, vol. 4, no. 4, pp. 243–250, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. Y. J. Surh, “Cancer chemoprevention with dietary phytochemicals,” Nature Reviews Cancer, vol. 3, no. 10, pp. 768–780, 2003. View at Publisher · View at Google Scholar · View at Scopus
  61. L. Rodríguez-Fragoso, J. L. Martínez-Arismendi, D. Orozco-Bustos, J. Reyes-Esparza, E. Torres, and S. W. Burchiel, “Potential risks resulting from fruit/vegetable-drug interactions: effects on drug-metabolizing enzymes and drug transporters,” Journal of Food Science, vol. 76, no. 4, pp. R112–R124, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. L. Korkina, C. De Luca, and S. Pastore, “Plant polyphenols and human skin: friends or foes,” Annals of the New York Academy of Sciences, vol. 1259, no. 1, pp. 77–86, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. Y. D. Muthiah, C. E. Ong, S. A. Sulaiman, S. C. Tan, and R. Ismail, “In-vitro inhibitory effect of Tualang honey on cytochrome P450 2C8 activity,” Journal of Pharmacy and Pharmacology, vol. 64, no. 12, pp. 1761–1769, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. D. Schwarz, P. Kisselev, W.-H. Schunck, and I. Roots, “Inhibition of 17β-estradiol activation by CYP1A1: genotype- and regioselective inhibition by St. John's Wort and several natural polyphenols,” Biochimica et Biophysica Acta—Proteins and Proteomics, vol. 1814, no. 1, pp. 168–174, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. J. M. Lillywhite, J. E. Simonsen, and V. Wilson, “Growing Chinese medicinal herbs in the United States: understanding practitioner preferences,” Agriculture and Human Values, vol. 29, no. 2, pp. 151–159, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. A. Jain, R. Sharma, N. Gahalain, J. Chaudary, and G. K. Gupta, “Herbal plants used in diabetic complications: an overview,” Journal of Pharmacy Research, vol. 4, no. 4, pp. 986–988, 2011. View at Google Scholar
  67. S. Zhou, Y. Gao, W. Jiang, M. Huang, A. Xu, and J. W. Paxton, “Interactions of herbs with cytochrome P450,” Drug Metabolism Reviews, vol. 35, no. 1, pp. 35–98, 2003. View at Publisher · View at Google Scholar · View at Scopus
  68. A. A. Izzo, “Herb-drug interactions: an overview of the clinical evidence,” Fundamental and Clinical Pharmacology, vol. 19, no. 1, pp. 1–16, 2005. View at Publisher · View at Google Scholar · View at Scopus
  69. P. H. Marathe and A. D. Rodrigues, “In vivo animal models for investigating potential CYP3A- and Pgp-mediated drug-drug interactions,” Current Drug Metabolism, vol. 7, no. 7, pp. 687–704, 2006. View at Publisher · View at Google Scholar · View at Scopus
  70. T. L. Poulos, “Cytochrome P450 dynamics,” in Fifty Years of Cytochrome P450 Research, pp. 75–94, Springer, Tokyo, Japan, 2014. View at Publisher · View at Google Scholar
  71. A. R. Topletz, J. B. Dennison, R. J. Barbuch, C. E. Hadden, S. D. Hall, and J. L. Renbarger, “The relative contributions of CYP3A4 and CYP3A5 to the metabolism of vinorelbine,” Drug Metabolism & Disposition, vol. 41, no. 9, pp. 1651–1661, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. S. J. Brantley, A. A. Argikar, Y. S. Lin, S. Nagar, and M. F. Paine, “Herb-drug interactions: challenges and opportunities for improved predictions,” Drug Metabolism and Disposition, vol. 42, no. 3, pp. 301–317, 2014. View at Publisher · View at Google Scholar · View at Scopus
  73. Y. Kimura, H. Ito, R. Ohnishi, and T. Hatano, “Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity,” Food and Chemical Toxicology, vol. 48, no. 1, pp. 429–435, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. I. Rodeiro, M. T. Donato, N. Jimenez et al., “Inhibition of human P450 enzymes by natural extracts used in traditional medicine,” Phytotherapy Research, vol. 23, no. 2, pp. 279–282, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. R. Z. Harris, G. R. Jang, and S. Tsunoda, “Dietary effects on drug metabolism and transport,” Clinical Pharmacokinetics, vol. 42, no. 13, pp. 1071–1088, 2003. View at Publisher · View at Google Scholar · View at Scopus
  76. D. G. Bailey, J. Malcolm, O. Arnold, and J. D. Spence, “Grapefruit juice-drug interactions,” British Journal of Clinical Pharmacology, vol. 46, no. 2, pp. 101–110, 1998. View at Publisher · View at Google Scholar · View at Scopus
  77. Y.-M. Ku, D. I. Min, and M. Flanigan, “Effect of grapefruit juice on the pharmacokinetics of microemulsion cyclosporine and its metabolite in healthy volunteers: does the formulation difference matter?” Journal of Clinical Pharmacology, vol. 38, no. 10, pp. 959–965, 1998. View at Publisher · View at Google Scholar · View at Scopus
  78. D. I. Min, Y.-M. Ku, P. J. Perry et al., “Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients1,” Transplantation, vol. 62, no. 1, pp. 123–125, 1996. View at Publisher · View at Google Scholar · View at Scopus
  79. J. S. Markowitz, J. L. Donovan, C. L. deVane et al., “Effect of St. John's Wort on drug metabolism by induction of cytochrome P450 3A4 enzyme,” Journal of the American Medical Association, vol. 290, no. 11, pp. 1500–1504, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. G. W. Barone, B. J. Gurley, B. L. Ketel, M. L. Lightfoot, and S. R. Abul-Ezz, “Drug interaction between St. John's wort and cyclosporine,” Annals of Pharmacotherapy, vol. 34, no. 9, pp. 1013–1016, 2000. View at Publisher · View at Google Scholar · View at Scopus
  81. H.-H. S. Chow, L. L. Garland, C.-H. Hsu et al., “Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study,” Cancer Prevention Research, vol. 3, no. 9, pp. 1168–1175, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. S. F. Zhou, C. C. Xue, X. Q. Yu, C. Li, and G. Wang, “Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring,” Therapeutic Drug Monitoring, vol. 29, no. 6, pp. 687–710, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. X.-W. Chen, K. B. Sneed, S.-Y. Pan et al., “Herb-drug interactions and mechanistic and clinical considerations,” Current Drug Metabolism, vol. 13, no. 5, pp. 640–651, 2012. View at Publisher · View at Google Scholar · View at Scopus
  84. F. Qiu, J. Jiang, Y. Ma et al., “Opposite effects of single-dose and multidose administration of the ethanol extract of danshen on CYP3A in healthy volunteers,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 730734, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  85. R. Rahimi and M. Abdollahi, “An update on the ability of St. John's wort to affect the metabolism of other drugs,” Expert Opinion on Drug Metabolism and Toxicology, vol. 8, no. 6, pp. 691–708, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. H. G. Xie and R. B. Kim, “St. John’s wort-associated drug interactions: Short-term inhibition and long-term induction?” Clinical Pharmacology & Therapeutics, vol. 78, no. 1, pp. 19–24, 2005. View at Google Scholar
  87. J. Patel, B. Buddha, S. Dey, D. Pal, and A. K. Mitra, “In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity,” The American Journal of Therapeutics, vol. 11, no. 4, pp. 262–277, 2004. View at Publisher · View at Google Scholar · View at Scopus
  88. T. M. Vijayakumar, R. M. Kumar, A. Agrawal, G. P. Dubey, and K. Ilango, “Comparative inhibitory potential of selected dietary bioactive polyphenols, phytosterols on CYP3A4 and CYP2D6 with fluorometric high-throughput screening,” Journal of Food Science and Technology, 2014. View at Publisher · View at Google Scholar
  89. S. J. Brantley, T. N. Graf, N. H. Oberlies, and M. F. Paine, “A systematic approach to evaluate herb-drug interaction mechanisms: investigation of milk thistle extracts and eight isolated constituents as CYP3A inhibitors,” Drug Metabolism and Disposition, vol. 41, no. 9, pp. 1662–1670, 2013. View at Publisher · View at Google Scholar · View at Scopus
  90. I. Rodeiro, M. J. Gómez-Lechón, G. Perez et al., “Mangifera indica L. extract and mangiferin modulate cytochrome P450 and UDP-glucuronosyltransferase enzymes in primary cultures of human hepatocytes,” Phytotherapy Research, vol. 27, no. 5, pp. 745–752, 2013. View at Publisher · View at Google Scholar · View at Scopus
  91. J. I. Boullata, “Drug and nutrition interactions: not just food for thought,” Journal of Clinical Pharmacy and Therapeutics, vol. 38, no. 4, pp. 269–271, 2013. View at Publisher · View at Google Scholar · View at Scopus
  92. O. A. Fahmi, T. S. Maurer, M. Kish, E. Cardenas, S. Boldt, and D. Nettleton, “A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3a4 inhibition, inactivation, and induction determined in vitro,” Drug Metabolism and Disposition, vol. 36, no. 8, pp. 1698–1708, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. Y.-H. Wang, D. R. Jones, and S. D. Hall, “Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites,” Drug Metabolism and Disposition, vol. 32, no. 2, pp. 259–266, 2004. View at Publisher · View at Google Scholar · View at Scopus
  94. J. A. Ross and C. M. Kasum, “Dietary flavonoids: bioavailability, metabolic effects, and safety,” Annual Review of Nutrition, vol. 22, pp. 19–34, 2002. View at Publisher · View at Google Scholar · View at Scopus
  95. A. Scalbert, I. T. Johnson, and M. Saltmarsh, “Polyphenols: antioxidants and beyond,” The American Journal of Clinical Nutrition, vol. 81, no. 1, pp. 215S–217S, 2005. View at Google Scholar · View at Scopus
  96. P. Chabert, C. Auger, J. Pincemail, and V. B. Schini-Kerth, “Overview of plant-derived antioxidants,” in Systems Biology of Free Radicals and Antioxidants, pp. 4005–4022, Springer, Berlin, Germany, 2014. View at Publisher · View at Google Scholar
  97. J. Pérez-Jiménez, M. E. Díaz-Rubio, and F. Saura-Calixto, “Non-extractable polyphenols, a major dietary antioxidant: occurrence, metabolic fate and health effects,” Nutrition Research Reviews, vol. 26, no. 2, pp. 118–129, 2013. View at Publisher · View at Google Scholar · View at Scopus
  98. M.-L. Ovaskainen, R. Törrönen, J. M. Koponen et al., “Dietary intake and major food sources of polyphenols in Finnish adults,” Journal of Nutrition, vol. 138, no. 3, pp. 562–566, 2008. View at Google Scholar · View at Scopus
  99. N. N. Thu, C. Sakurai, H. Uto et al., “The polyphenol content and antioxidant activities of the main edible vegetables in Northern Vietnam,” Journal of Nutritional Science and Vitaminology, vol. 50, no. 3, pp. 203–210, 2004. View at Publisher · View at Google Scholar · View at Scopus
  100. F. Saura-Calixto, J. Serrano, and I. Goñi, “Intake and bioaccessibility of total polyphenols in a whole diet,” Food Chemistry, vol. 101, no. 2, pp. 492–501, 2007. View at Publisher · View at Google Scholar · View at Scopus
  101. J. Kanner and T. Lapidot, “The stomach as a bioreactor: dietary lipid peroxidation in the gastric fluid and the effects of plant-derived antioxidants,” Free Radical Biology & Medicine, vol. 31, no. 11, pp. 1388–1395, 2001. View at Publisher · View at Google Scholar · View at Scopus
  102. Z. Kerem, D. Chetrit, O. Shoseyov, and G. Regev-Shoshani, “Protection of lipids from oxidation by epicatechin, trans-resveratrol, and gallic and caffeic acids in intestinal model systems,” Journal of Agricultural and Food Chemistry, vol. 54, no. 26, pp. 10288–10293, 2006. View at Publisher · View at Google Scholar · View at Scopus
  103. C. J. Dufresne and E. R. Farnworth, “A review of latest research findings on the health promotion properties of tea,” Journal of Nutritional Biochemistry, vol. 12, no. 7, pp. 404–421, 2001. View at Publisher · View at Google Scholar · View at Scopus
  104. F. Shahidi and Y. Zhong, “Novel antioxidants in food quality preservation and health promotion,” European Journal of Lipid Science and Technology, vol. 112, no. 9, pp. 930–940, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. N. Khan and H. Mukhtar, “Cancer and metastasis: prevention and treatment by green tea,” Cancer and Metastasis Reviews, vol. 29, no. 3, pp. 435–445, 2010. View at Publisher · View at Google Scholar · View at Scopus
  106. B. B. Aggarwal and S. Shishodia, “Molecular targets of dietary agents for prevention and therapy of cancer,” Biochemical Pharmacology, vol. 71, no. 10, pp. 1397–1421, 2006. View at Publisher · View at Google Scholar · View at Scopus
  107. G. Garrido, D. González, Y. Lemus et al., “In vivo and in vitro anti-inflammatory activity of Mangifera indica L. extract (VIMANG),” Pharmacological Research, vol. 50, no. 2, pp. 143–149, 2004. View at Publisher · View at Google Scholar · View at Scopus
  108. S. N. Nichenametla, T. G. Taruscio, D. L. Barney, and J. H. Exon, “A review of the effects and mechanisms of polyphenolics in cancer,” Critical Reviews in Food Science and Nutrition, vol. 46, no. 2, pp. 161–183, 2006. View at Publisher · View at Google Scholar · View at Scopus
  109. N. T. Zaveri, “Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications,” Life Sciences, vol. 78, no. 18, pp. 2073–2080, 2006. View at Publisher · View at Google Scholar · View at Scopus
  110. N. Kalogeropoulos, K. Yannakopoulou, A. Gioxari, A. Chiou, and D. P. Makris, “Polyphenol characterization and encapsulation in β-cyclodextrin of a flavonoid-rich Hypericum perforatum (St John's wort) extract,” LWT—Food Science and Technology, vol. 43, no. 6, pp. 882–889, 2010. View at Publisher · View at Google Scholar · View at Scopus
  111. H. J. Lee, H.-S. Lee, H. J. Cho, S. Y. Kim, and H. J. Suh, “Utilization of hydrolytic enzymes for the extraction of ginsenosides from Korean ginseng leaves,” Process Biochemistry, vol. 47, no. 3, pp. 538–543, 2012. View at Publisher · View at Google Scholar · View at Scopus
  112. M. Maizura, A. Aminah, and W. M. W. Aida, “Total phenolic content and antioxidant activity of kesum (Polygonum minus), ginger (Zingiber officinale) and turmeric (Curcuma longa) extract,” International Food Research Journal, vol. 18, no. 2, pp. 529–534, 2011. View at Google Scholar · View at Scopus
  113. B. Jiang, F. Kronenberg, M. J. Balick, and E. J. Kennelly, “Stability of black cohosh triterpene glycosides and polyphenols: potential clinical relevance,” Phytomedicine, vol. 20, no. 6, pp. 564–569, 2013. View at Publisher · View at Google Scholar · View at Scopus
  114. S. S. Georgieva, V. L. Christova-Bagdassarian, and M. S. Atanassova, “Comparative evaluation of the polyphenol composition and antioxidant capacity of propolis and Echinacea purpurea,” Journal of Experimental and Integrative Medicine, vol. 4, no. 1, pp. 51–56, 2014. View at Publisher · View at Google Scholar
  115. F. F. Anhê, D. Roy, G. Pilon et al., “A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice,” Gut, 2014. View at Publisher · View at Google Scholar
  116. A. R. Rechner, G. Kuhnle, P. Bremner, G. P. Hubbard, K. P. Moore, and C. A. Rice-Evans, “The metabolic fate of dietary polyphenols in humans,” Free Radical Biology and Medicine, vol. 33, no. 2, pp. 220–235, 2002. View at Publisher · View at Google Scholar · View at Scopus
  117. L. Bravo, “Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance,” Nutrition Reviews, vol. 56, no. 11, pp. 317–333, 1998. View at Google Scholar · View at Scopus
  118. H. Doostdar, M. D. Burke, and R. T. Mayer, “Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1,” Toxicology, vol. 144, no. 1–3, pp. 31–38, 2000. View at Publisher · View at Google Scholar · View at Scopus
  119. C. Rice-Evans, “Flavonoid antioxidants,” Current Medicinal Chemistry, vol. 8, no. 7, pp. 797–807, 2001. View at Publisher · View at Google Scholar · View at Scopus
  120. P. Jančová, E. Anzenbacherová, B. Papoušková et al., “Silybin is metabolized by cytochrome P450 2C8 in vitro,” Drug Metabolism & Disposition, vol. 35, no. 11, pp. 2035–2039, 2007. View at Publisher · View at Google Scholar · View at Scopus
  121. C. S. Yang and E. Pan, “The effects of green tea polyphenols on drug metabolism,” Expert Opinion on Drug Metabolism and Toxicology, vol. 8, no. 6, pp. 677–689, 2012. View at Publisher · View at Google Scholar · View at Scopus
  122. S. Sang, J. D. Lambert, C.-T. Ho, and C. S. Yang, “The chemistry and biotransformation of tea constituents,” Pharmacological Research, vol. 64, no. 2, pp. 87–99, 2011. View at Publisher · View at Google Scholar · View at Scopus
  123. R. Didziapetris, J. Dapkunas, A. Sazonovas, and P. Japertas, “Trainable structure-activity relationship model for virtual screening of CYP3A4 inhibition,” Journal of Computer-Aided Molecular Design, vol. 24, no. 11, pp. 891–906, 2010. View at Publisher · View at Google Scholar · View at Scopus
  124. K. Roy and P. P. Roy, “QSAR of cytochrome inhibitors,” Expert Opinion on Drug Metabolism and Toxicology, vol. 5, no. 10, pp. 1245–1266, 2009. View at Publisher · View at Google Scholar · View at Scopus
  125. S. Misaka, K. Kawabe, S. Onoue et al., “Green tea extract affects the cytochrome P450 3A activity and pharmacokinetics of simvastatin in rats,” Drug Metabolism and Pharmacokinetics, vol. 28, no. 6, pp. 514–518, 2013. View at Publisher · View at Google Scholar · View at Scopus
  126. M. Nishikawa, N. Ariyoshi, A. Kotani et al., “Effects of continuous ingestion of green tea or grape seed extracts on the pharmacokinetics of midazolam,” Drug Metabolism and Pharmacokinetics, vol. 19, no. 4, pp. 280–289, 2004. View at Publisher · View at Google Scholar · View at Scopus
  127. A. Amri, J. C. Chaumeil, S. Sfar, and C. Charrueau, “Administration of resveratrol: what formulation solutions to bioavailability limitations?” Journal of Controlled Release, vol. 158, no. 2, pp. 182–193, 2012. View at Publisher · View at Google Scholar · View at Scopus
  128. T. Walle, “Bioavailability of resveratrol,” Annals of the New York Academy of Sciences, vol. 1215, no. 1, pp. 9–15, 2011. View at Publisher · View at Google Scholar · View at Scopus
  129. J.-F. Marier, P. Vachon, A. Gritsas, J. Zhang, J.-P. Moreau, and M. P. Ducharme, “Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model,” Journal of Pharmacology and Experimental Therapeutics, vol. 302, no. 1, pp. 369–373, 2002. View at Publisher · View at Google Scholar · View at Scopus
  130. G. Singh and R. S. Pai, “In-vitro/in-vivo characterization of trans-resveratrol-loaded nanoparticulate drug delivery system for oral administration,” Journal of Pharmacy and Pharmacology, vol. 66, no. 8, pp. 1062–1076, 2014. View at Publisher · View at Google Scholar
  131. K. B. Seljak, K. Berginc, J. Trontelj, A. Zvonar, A. Kristl, and M. Gašperlin, “A self-microemulsifying drug delivery system to overcome intestinal resveratrol toxicity and presystemic metabolism,” Journal of Pharmaceutical Sciences, vol. 103, no. 11, pp. 3491–3500, 2014. View at Publisher · View at Google Scholar
  132. S. G. Parkar, T. M. Trower, and D. E. Stevenson, “Fecal microbial metabolism of polyphenols and its effects on human gut microbiota,” Anaerobe, vol. 23, pp. 12–19, 2013. View at Publisher · View at Google Scholar · View at Scopus
  133. S. G. Parkar, D. E. Stevenson, and M. A. Skinner, “The potential influence of fruit polyphenols on colonic microflora and human gut health,” International Journal of Food Microbiology, vol. 124, no. 3, pp. 295–298, 2008. View at Publisher · View at Google Scholar · View at Scopus
  134. S. Bolca, T. van de Wiele, and S. Possemiers, “Gut metabotypes govern health effects of dietary polyphenols,” Current Opinion in Biotechnology, vol. 24, no. 2, pp. 220–225, 2013. View at Publisher · View at Google Scholar · View at Scopus
  135. C. Morand, C. Dubray, D. Milenkovic et al., “Hesperidin contributes to the vascular protective effects of orange juice: a randomized crossover study in healthy volunteers,” The American Journal of Clinical Nutrition, vol. 93, no. 1, pp. 73–80, 2011. View at Publisher · View at Google Scholar · View at Scopus
  136. J. W. Lampe, “Interindividual differences in response to plant-based diets: implications for cancer risk,” The American Journal of Clinical Nutrition, vol. 89, no. 5, pp. 1553S–1557S, 2009. View at Publisher · View at Google Scholar · View at Scopus
  137. S. Stoupi, G. Williamson, J. W. Drynan, D. Barron, and M. N. Clifford, “A comparison of the in vitro biotransformation of (-)-epicatechin and procyanidin B2 by human faecal microbiota,” Molecular Nutrition and Food Research, vol. 54, no. 6, pp. 747–759, 2010. View at Publisher · View at Google Scholar · View at Scopus
  138. G. K. Dresser, J. D. Spence, and D. G. Bailey, “Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition,” Clinical Pharmacokinetics, vol. 38, no. 1, pp. 41–57, 2000. View at Publisher · View at Google Scholar · View at Scopus
  139. S. Muto, K.-I. Fujita, Y. Yamazaki, and T. Kamataki, “Inhibition by green tea catechins of metabolic activation of procarcinogens by human cytochrome P450,” Mutation Research—Fundamental and Molecular Mechanisms of Mutagenesis, vol. 479, no. 1-2, pp. 197–206, 2001. View at Publisher · View at Google Scholar · View at Scopus
  140. C. R. Wolf, “Chemoprevention: increased potential to bear fruit,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 6, pp. 2941–2943, 2001. View at Publisher · View at Google Scholar · View at Scopus
  141. S. Parys, S. Kehraus, A. Krick et al., “In vitro chemopreventive potential of fucophlorethols from the brown alga Fucus vesiculosus L. by anti-oxidant activity and inhibition of selected cytochrome P450 enzymes,” Phytochemistry, vol. 71, no. 2-3, pp. 221–229, 2010. View at Publisher · View at Google Scholar · View at Scopus
  142. M. Athar, J. H. Back, X. Tang et al., “Resveratrol: a review of preclinical studies for human cancer prevention,” Toxicology and Applied Pharmacology, vol. 224, no. 3, pp. 274–283, 2007. View at Publisher · View at Google Scholar · View at Scopus
  143. K. Sahu, A. A. Siddiqui, M. Shaharyar, and S. Malik, “Pharmacokinetic interaction between febuxostat and morin in rats,” Expert Opinion on Drug Metabolism and Toxicology, vol. 10, no. 3, pp. 307–312, 2014. View at Publisher · View at Google Scholar · View at Scopus
  144. K. K. Kumar, L. Priyanka, K. Gnananath, P. R. Babu, and S. Sujatha, “Pharmacokinetic drug interactions between apigenin, rutin and paclitaxel mediated by P-glycoprotein in rats,” European Journal of Drug Metabolism and Pharmacokinetics, 2014. View at Publisher · View at Google Scholar · View at Scopus
  145. A. Ferreira, S. Pousinho, A. Fortuna, A. Falcão, and G. Alves, “Flavonoid compounds as reversal agents of the P-glycoprotein-mediated multidrug resistance: biology, chemistry and pharmacology,” Phytochemistry Reviews, 2014. View at Publisher · View at Google Scholar · View at Scopus
  146. B. T. Gufford, G. Chen, P. Lazarus, T. N. Graf, N. H. Oberlies, and M. F. Paine, “Identification of diet-derived constituents as potent inhibitors of intestinal glucuronidation,” Drug Metabolism & Disposition, vol. 42, no. 10, pp. 1675–1683, 2014. View at Publisher · View at Google Scholar
  147. X. F. Koe, T. S. T. Muhammad, A. S. C. Chong, H. Abdul Wahab, and M. L. Tan, “Cytochrome P450 induction properties of food and herbal-derived compounds using a novel multiplex RT-qPCR in vitro assay, a drug-food interaction prediction tool,” Food Science & Nutrition, vol. 2, no. 5, pp. 500–520, 2014. View at Publisher · View at Google Scholar
  148. T. Shimada, K. Tanaka, S. Takenaka et al., “Structure-function relationships of inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid derivatives,” Chemical Research in Toxicology, vol. 23, no. 12, pp. 1921–1935, 2010. View at Publisher · View at Google Scholar · View at Scopus
  149. M. A. Sarkar, G. Scambia, F. O. Ranelletti et al., “Quercetin not only inhibits P-glycoprotein efflux activity but also inhibits CYP3A isozymes,” Cancer Chemotherapy and Pharmacology, vol. 36, no. 5, pp. 448–449, 1995. View at Publisher · View at Google Scholar · View at Scopus
  150. J.-S. Choi, Y.-J. Piao, and K. W. Kang, “Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin,” Archives of Pharmacal Research, vol. 34, no. 4, pp. 607–613, 2011. View at Publisher · View at Google Scholar · View at Scopus
  151. C.-P. Yu, P.-P. Wu, Y.-C. Hou et al., “Quercetin and rutin reduced the bioavailability of cyclosporine from Neoral, an immunosuppressant, through activating P-glycoprotein and CYP 3A4,” Journal of Agricultural and Food Chemistry, vol. 59, no. 9, pp. 4644–4648, 2011. View at Publisher · View at Google Scholar · View at Scopus
  152. J. Rashid, C. McKinstry, A. G. Renwick, M. Dirnhuber, D. G. Waller, and C. F. George, “Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice,” British Journal of Clinical Pharmacology, vol. 36, no. 5, pp. 460–463, 1993. View at Publisher · View at Google Scholar · View at Scopus
  153. J. L. Raucy, “Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products,” Drug Metabolism and Disposition, vol. 31, no. 5, pp. 533–539, 2003. View at Publisher · View at Google Scholar · View at Scopus
  154. W. C. Lau, T. D. Welch, T. Shields, M. Rubenfire, U. S. Tantry, and P. A. Gurbel, “The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity,” Journal of Cardiovascular Pharmacology, vol. 57, no. 1, pp. 86–93, 2011. View at Publisher · View at Google Scholar · View at Scopus
  155. A. Kamel and S. Harriman, “Inhibition of cytochrome P450 enzymes and biochemical aspects of mechanism-based inactivation (MBI),” Drug Discovery Today: Technologies, vol. 10, no. 1, pp. e177–e189, 2013. View at Publisher · View at Google Scholar · View at Scopus
  156. L. Quintieri, P. Palatini, A. Nassi, P. Ruzza, and M. Floreani, “Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP 3A4 and CYP3A5 enzymes,” Biochemical Pharmacology, vol. 75, no. 6, pp. 1426–1437, 2008. View at Publisher · View at Google Scholar · View at Scopus
  157. E. V. Sineva, J. A. O. Rumfeldt, J. R. Halpert, and D. R. Davydov, “A large-scale allosteric transition in cytochrome P450 3A4 revealed by luminescence resonance energy transfer (LRET),” PLoS ONE, vol. 8, no. 12, Article ID e83898, 2013. View at Publisher · View at Google Scholar · View at Scopus
  158. D. R. Davydov, N. Y. Davydova, E. V. Sineva, I. Kufareva, and J. R. Halpert, “Pivotal role of P450-P450 interactions in CYP3A4 allostery: the case of α-naphthoflavone,” Biochemical Journal, vol. 453, no. 2, pp. 219–230, 2013. View at Publisher · View at Google Scholar · View at Scopus
  159. D. R. Davydov, J. A. O. Rumfeldt, E. V. Sineva, H. Fernando, N. Y. Davydova, and J. R. Halpert, “Peripheral ligand-binding site in cytochrome P450 3A4 located with fluorescence resonance energy transfer (FRET),” Journal of Biological Chemistry, vol. 287, no. 9, pp. 6797–6809, 2012. View at Publisher · View at Google Scholar · View at Scopus
  160. D. J. Frank, I. G. Denisov, and S. G. Sligar, “Analysis of heterotropic cooperativity in cytochrome P450 3A4 using α-naphthoflavone and testosterone,” Journal of Biological Chemistry, vol. 286, no. 7, pp. 5540–5545, 2011. View at Publisher · View at Google Scholar · View at Scopus
  161. A. G. Roberts and W. M. Atkins, “Energetics of heterotropic cooperativity between α-naphthoflavone and testosterone binding to CYP3A4,” Archives of Biochemistry and Biophysics, vol. 463, no. 1, pp. 89–101, 2007. View at Publisher · View at Google Scholar · View at Scopus
  162. M. I. Netsch, H. Gutmann, C. B. Schmidlin, C. Aydogan, and J. Drewe, “Induction of CYP1A by green tea extract in human intestinal cell lines,” Planta Medica, vol. 72, no. 6, pp. 514–520, 2006. View at Publisher · View at Google Scholar · View at Scopus
  163. D. G. Bailey, J. M. O. Arnold, and J. D. Spence, “Grapefruit juice and drugs. How significant is the interaction?” Clinical Pharmacokinetics, vol. 26, no. 2, pp. 91–98, 1994. View at Publisher · View at Google Scholar · View at Scopus
  164. U. Fuhr and A. L. Kummert, “The fata of naringin in humans: a key to grapefruit juice-drug interactions?” Clinical Pharmacology and Therapeutics, vol. 58, no. 4, pp. 365–373, 1995. View at Publisher · View at Google Scholar · View at Scopus
  165. P.-C. Ho, D. J. Saville, and S. Wanwimolruk, “Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds,” Journal of Pharmacy & Pharmaceutical Sciences, vol. 4, no. 3, pp. 217–227, 2001. View at Google Scholar · View at Scopus
  166. K. Iwanaga, M. Hayashi, Y. Hamahata et al., “Furanocoumarin derivatives in Kampo extract medicines inhibit cytochrome P450 3A4 and P-glycoprotein,” Drug Metabolism and Disposition, vol. 38, no. 8, pp. 1286–1294, 2010. View at Publisher · View at Google Scholar · View at Scopus
  167. K. M. VanderMolen, G. R. Ainslie, M. F. Paine, and N. H. Oberlies, “Labeled content of two furanocoumarins in dietary supplements correlates with neither actual content nor CYP3A inhibitory activity,” Journal of Pharmaceutical and Biomedical Analysis, vol. 98, pp. 260–265, 2014. View at Publisher · View at Google Scholar
  168. Y.-F. Ueng, C.-C. Chen, H. Yamazaki et al., “Mechanism-based inhibition of CYP1A1 and CYP3A4 by the furanocoumarin chalepensin,” Drug Metabolism and Pharmacokinetics, vol. 28, no. 3, pp. 229–238, 2013. View at Publisher · View at Google Scholar · View at Scopus
  169. B. C. Foster, S. Vandenhoek, J. Hana et al., “In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products,” Phytomedicine, vol. 10, no. 4, pp. 334–342, 2003. View at Publisher · View at Google Scholar · View at Scopus
  170. E. S. Roberts-Kirchhoff, J. R. Crowley, P. F. Hollenberg, and H. Kim, “Metabolism of genistein by rat and human cytochrome P450s,” Chemical Research in Toxicology, vol. 12, no. 7, pp. 610–616, 1999. View at Publisher · View at Google Scholar · View at Scopus
  171. L. M. Scott, P. Durant, S. Leone-Kabler et al., “Effects of prior oral contraceptive use and soy isoflavonoids on estrogen-metabolizing cytochrome P450 enzymes,” Journal of Steroid Biochemistry and Molecular Biology, vol. 112, no. 4-5, pp. 179–185, 2008. View at Publisher · View at Google Scholar · View at Scopus
  172. C.-Q. Xiao, R. Chen, J. Lin et al., “Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants,” Xenobiotica, vol. 42, no. 2, pp. 173–178, 2012. View at Publisher · View at Google Scholar · View at Scopus
  173. Y. Chen, C.-Q. Xiao, Y.-J. He et al., “Genistein alters caffeine exposure in healthy female volunteers,” European Journal of Clinical Pharmacology, vol. 67, no. 4, pp. 347–353, 2011. View at Publisher · View at Google Scholar · View at Scopus
  174. A. Dreiseitel, P. Schreier, A. Oehme, S. Locher, G. Hajak, and P. G. Sand, “Anthocyanins and their metabolites are weak inhibitors of cytochrome P450 3A4,” Molecular Nutrition and Food Research, vol. 52, no. 12, pp. 1428–1433, 2008. View at Publisher · View at Google Scholar · View at Scopus
  175. W. K. Chan and A. B. Delucchi, “Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4,” Life Sciences, vol. 67, no. 25, pp. 3103–3112, 2000. View at Publisher · View at Google Scholar · View at Scopus
  176. B. Piver, F. Berthou, Y. Dreano, and D. Lucas, “Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components,” Toxicology Letters, vol. 125, no. 1–3, pp. 83–91, 2001. View at Publisher · View at Google Scholar · View at Scopus
  177. S.-P. Hong, D.-H. Choi, and J.-S. Choi, “Effects of resveratrol on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem, in rats,” Cardiovascular Therapeutics, vol. 26, no. 4, pp. 269–275, 2008. View at Publisher · View at Google Scholar · View at Scopus
  178. Y. C. Chi, S. P. Lin, and Y. C. Hou, “A new herb-drug interaction of Polygonum cuspidatum, a resveratrol-rich nutraceutical, with carbamazepine in rats,” Toxicology and Applied Pharmacology, vol. 263, no. 3, pp. 315–322, 2012. View at Publisher · View at Google Scholar · View at Scopus
  179. P. Detampel, M. Beck, S. Krähenbühl, and J. Huwyler, “Drug interaction potential of resveratrol,” Drug Metabolism Reviews, vol. 44, no. 3, pp. 253–265, 2012. View at Publisher · View at Google Scholar · View at Scopus
  180. M. A. Correia and P. R. O. de Montellano, “Inhibition of cytochrome P450 enzymes,” in Cytochrome P450, pp. 247–322, Springer, Berlin, Germany, 3rd edition, 2005. View at Google Scholar
  181. Y. Sahali-Sahly, S. K. Balani, J. H. Lin, and T. A. Baillie, “In vitro studies on the metabolic activation of the furanopyridine L- 754,394, a highly potent and selective mechanism-based inhibitor of cytochrome P450 3A4,” Chemical Research in Toxicology, vol. 9, no. 6, pp. 1007–1012, 1996. View at Publisher · View at Google Scholar · View at Scopus
  182. H. Iwata, Y. Tezuka, S. Kadota, A. Hiratsuka, and T. Watabe, “Identification and characterization of potent CYP3A4 inhibitors in Schisandra fruit extract,” Drug Metabolism and Disposition, vol. 32, no. 12, pp. 1351–1358, 2004. View at Publisher · View at Google Scholar · View at Scopus
  183. R. Venkataramanan, V. Ramachandran, B. J. Komoroski, S. Zhang, P. L. Schiff, and S. C. Strom, “Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures,” Drug Metabolism and Disposition, vol. 28, no. 11, pp. 1270–1273, 2000. View at Google Scholar · View at Scopus
  184. R. Zuber, M. Modrianský, Z. Dvořák et al., “Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities,” Phytotherapy Research, vol. 16, no. 7, pp. 632–638, 2002. View at Publisher · View at Google Scholar · View at Scopus
  185. H.-T. Yao, Y.-W. Chang, S.-J. Lan, and T.-K. Yeh, “The inhibitory effect of tannic acid on cytochrome P450 enzymes and NADPH-CYP reductase in rat and human liver microsomes,” Food and Chemical Toxicology, vol. 46, no. 2, pp. 645–653, 2008. View at Publisher · View at Google Scholar · View at Scopus
  186. C. Jaikang, K. Niwatananun, P. Narongchai, S. Narongchai, and C. Chaiyasut, “Inhibitory effect of caffeic acid and its derivatives on human liver cytochrome P450 3A4 activity,” Journal of Medicinal Plants Research, vol. 5, no. 15, pp. 3530–3536, 2011. View at Google Scholar · View at Scopus
  187. I. Stupans, G. Stretch, and P. Hayball, “Olive oil phenols inhibit human hepatic microsomal activity,” Journal of Nutrition, vol. 130, no. 9, pp. 2367–2370, 2000. View at Google Scholar · View at Scopus
  188. I. Stupans, H.-W. Tan, A. Kirlich, K. Tuck, P. Hayball, and M. Murray, “Inhibition of CYP3A-mediated oxidation in human hepatic microsomes by the dietary derived complex phenol, gallic acid,” Journal of Pharmacy and Pharmacology, vol. 54, no. 2, pp. 269–275, 2002. View at Publisher · View at Google Scholar · View at Scopus
  189. J. K. Yano, M. R. Wester, G. A. Schoch, K. J. Griffin, C. D. Stout, and E. F. Johnson, “The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-Å resolution,” The Journal of Biological Chemistry, vol. 279, no. 37, pp. 38091–38094, 2004. View at Publisher · View at Google Scholar · View at Scopus
  190. P. A. Williams, J. Cosme, D. M. Vinković et al., “Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone,” Science, vol. 305, no. 5684, pp. 683–686, 2004. View at Publisher · View at Google Scholar · View at Scopus
  191. J. Sridhar, J. Liu, M. Foroozesh, and C. L. K. Stevens, “Insights on cytochrome P450 enzymes and inhibitors obtained through QSAR studies,” Molecules, vol. 17, no. 8, pp. 9283–9305, 2012. View at Publisher · View at Google Scholar · View at Scopus
  192. D. F. V. Lewis and B. G. Lake, “Molecular modelling and quantitative structure-activity relationship studies on the interaction of omeprazole with cytochrome P450 isozymes,” Toxicology, vol. 125, no. 1, pp. 31–44, 1998. View at Publisher · View at Google Scholar · View at Scopus
  193. S. Ekins, G. Bravi, J. H. Wikel, and S. A. Wrighton, “Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates,” Journal of Pharmacology and Experimental Therapeutics, vol. 291, no. 1, pp. 424–433, 1999. View at Google Scholar · View at Scopus
  194. S. Ekins, M. J. de Groot, and J. P. Jones, “Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites,” Drug Metabolism and Disposition, vol. 29, no. 7, pp. 936–944, 2001. View at Google Scholar · View at Scopus
  195. A. Galetin, S. E. Clarke, and J. B. Houston, “Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine,” Drug Metabolism and Disposition, vol. 31, no. 9, pp. 1108–1116, 2003. View at Publisher · View at Google Scholar · View at Scopus
  196. K. Ohkura, Y. Kawaguchi, Y. Watanabe, Y. Masubuchi, Y. Shinohara, and H. Hori, “Flexible structure of cytochrome P450: promiscuity of ligand binding in the CYP3A4 heme pocket,” Anticancer Research, vol. 29, no. 3, pp. 935–942, 2009. View at Google Scholar · View at Scopus
  197. K. E. Kenworthy, S. E. Clarke, J. Andrews, and J. B. Houston, “Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism,” Drug Metabolism and Disposition, vol. 29, no. 12, pp. 1644–1651, 2001. View at Google Scholar · View at Scopus
  198. M. Ekroos and T. Sjögren, “Structural basis for ligand promiscuity in cytochrome P450 3A4,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 37, pp. 13682–13687, 2006. View at Publisher · View at Google Scholar · View at Scopus
  199. I. G. Denisov, D. J. Frank, and S. G. Sligar, “Cooperative properties of cytochromes P450,” Pharmacology & Therapeutics, vol. 124, no. 2, pp. 151–167, 2009. View at Publisher · View at Google Scholar · View at Scopus
  200. W. M. Atkins, “Non-Michaelis-Menten kinetics in cytochrome P450-catalyzed reactions,” Annual Review of Pharmacology and Toxicology, vol. 45, pp. 291–310, 2005. View at Publisher · View at Google Scholar · View at Scopus
  201. J. M. Hutzler and T. S. Tracy, “Atypical kinetic profiles in drug metabolism reactions,” Drug Metabolism and Disposition, vol. 30, no. 4, pp. 355–362, 2002. View at Publisher · View at Google Scholar · View at Scopus
  202. D. R. Davydov and J. R. Halpert, “Allosteric P450 mechanisms: multiple binding sites, multiple conformers of both?” Expert Opinion on Drug Metabolism and Toxicology, vol. 4, no. 12, pp. 1523–1535, 2008. View at Publisher · View at Google Scholar · View at Scopus
  203. I. G. Denisov and S. G. Sligar, “A novel type of allosteric regulation: functional cooperativity in monomeric proteins,” Archives of Biochemistry and Biophysics, vol. 519, no. 2, pp. 91–102, 2012. View at Publisher · View at Google Scholar · View at Scopus
  204. D. F. Lewis, B. G. Lake, and M. Dickins, “Quantitative structure-activity relationships (QSARs) in inhibitors of various cytochromes P450: the importance of compound lipophilicity,” Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 22, no. 1, pp. 1–6, 2007. View at Publisher · View at Google Scholar · View at Scopus
  205. D. F. V. Lewis, B. G. Lake, and M. Dickins, “Quantitative structure-activity relationships (QSARs) in CYP3A4 inhibitors: the importance of lipophilic character and hydrogen bonding,” Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 21, no. 2, pp. 127–132, 2006. View at Publisher · View at Google Scholar · View at Scopus
  206. B. Mao, R. Gozalbes, F. Barbosa et al., “QSAR modeling of in vitro inhibition of cytochrome P450 3A4,” Journal of Chemical Information and Modeling, vol. 46, no. 5, pp. 2125–2134, 2006. View at Publisher · View at Google Scholar · View at Scopus
  207. P. Matoušková, H. Bártíková, I. Boušová et al., “Effect of defined green tea extract in various dosage schemes on drug-metabolizing enzymes in mice in vivo,” Journal of Functional Foods, vol. 10, pp. 327–335, 2014. View at Publisher · View at Google Scholar
  208. U. F. Ezuruike and J. M. Prieto, “The use of plants in the traditional management of diabetes in Nigeria: pharmacological and toxicological considerations,” Journal of Ethnopharmacology, vol. 155, no. 2, pp. 857–924, 2014. View at Publisher · View at Google Scholar
  209. C. Bunchorntavakul and K. R. Reddy, “Review article: herbal and dietary supplement hepatotoxicity,” Alimentary Pharmacology and Therapeutics, vol. 37, no. 1, pp. 3–17, 2013. View at Publisher · View at Google Scholar · View at Scopus
  210. E. J. Y. Kim, Y. Chen, J. Q. Huang et al., “Evidence-based toxicity evaluation and scheduling of Chinese herbal medicines,” Journal of Ethnopharmacology, vol. 146, no. 1, pp. 40–61, 2013. View at Publisher · View at Google Scholar · View at Scopus
  211. V. S. Neergheen-Bhujun, “Underestimating the toxicological challenges associated with the use of herbal medicinal products in developing countries,” BioMed Research International, vol. 2013, Article ID 804086, 9 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus